Robotic surgery for upper tract urothelial cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the safety and effectiveness of radical nephroureterectomy performed using the single-port Da Vinci SP Surgical System for patients with upper tract urothelial cancer. It focuses on assessing surgical outcomes, patient characteristics, and patient-reported outcomes following the procedure. The study aims to provide insights into the feasibility and benefits of this minimally invasive surgical approach.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age 20 years or more
* Histologically or cytologically diagnosed upper tract urothelial cancer
* Fitting indications of radical nephroureterectomy and ipsilateral bladder cuff resection, and deemed feasible for robotic surgery
* ASA physical status classification 1-2 and adequate organ function
* Patients willing and able to comply with study protocol requirements and follow-up
* With informed consent

Exclusion Criteria:

* Synchronous bladder cancer
* Distant metastasis of cancer
* BMI ≥30 or BMI \<18.5
* Unable to tolerate lateral decubitus or Trendelenburg position (relative contra-indication)
* Severe adhesion due to prior abdominopelvic surgery (relative contra-indication)
* Previous radiation treatment to the pelvic area
* Active infectious disease
* Severe concomitant illness that drastically shortens life expectancy or increases risk of therapeutic interventions, such as: severe heart disease (NYHA functional class III-IV) or severe lung disease (GOLD Group C-D)
* Cannot follow trial-required procedures
* Concomitant systemic or pelvic disease that increases the risk of surgery
* Long-term use of anti-coagulant(s)
* Patients with coagulopathy
* Emergency surgery

Where it's running

• National Taiwan University Hospital
  Taipei, Taiwan Recruiting

Study contacts

• Study coordinator: Shih-Chieh Chueh, Director
• Email: jeffchueh@gmail.com
• Phone: 02 23123456

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Specimen Collection for Validation of a New urine-based bladder cancer test

  This study collects urine and tumor samples from adults being evaluated or treated for urothelial cancer to validate a next‑generation sequencing platform.

  Recruiting Convergent Genomics, Inc. · Oceanside, California and 22 other locations · NCT07673016

• Sequential gemcitabine plus Jelmyto for favorable high-grade upper tract urothelial cancer

  This trial tests whether giving gemcitabine followed by Jelmyto directly into the kidney can control favorable high‑grade upper tract urothelial cancer and help people avoid kidney removal.

  Recruiting Phase 2 Rutgers, The State University of New Jersey · New Brunswick, New Jersey · NCT06822010

• Examining gene alterations and chemotherapy response in advanced bladder cancer

  This study is testing if certain gene changes can help predict how well advanced bladder cancer patients will respond to platinum-based chemotherapy treatments.

  Recruiting Phase 4 Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Rome · NCT06820255

• Registry for assessing the effects of Upper Tract Urothelial Cancer

  This study is creating a registry to gather information and samples from patients with Upper Tract Urothelial Cancer to help improve understanding and treatment of the disease.

  Recruiting Chinese University of Hong Kong · Hong Kong · NCT05438537

• Urinary Cell-Free DNA Test for Urothelial Cancer Origin

  This study tests a urine-based cell-free DNA test to help diagnose urothelial cancer and identify whether it started in the bladder or upper urinary tract in adults.

  Recruiting Ruijin Hospital · Shanghai · NCT07888374

• Blood test for detecting tumor DNA in bladder and upper tract cancer

  A blood test that looks for tumor DNA in people with muscle-invasive bladder cancer or upper tract urothelial cancer is being tested to see if it matches what’s found in tumor tissue and if it can help track recurrence or remission over two years.

  Recruiting AZ Sint-Lucas Gent · Ghent, East Flanders · NCT07756437

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.